1. Home
  2. KE vs PRTA Comparison

KE vs PRTA Comparison

Compare KE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimball Electronics Inc.

KE

Kimball Electronics Inc.

HOLD

Current Price

$29.46

Market Cap

459.3M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$11.02

Market Cap

472.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KE
PRTA
Founded
1961
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
459.3M
472.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KE
PRTA
Price
$29.46
$11.02
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$28.00
$18.86
AVG Volume (30 Days)
149.0K
603.3K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
91.88
N/A
EPS
0.96
N/A
Revenue
$1,478,074,000.00
$11,786,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.71
$819.08
P/E Ratio
$30.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.41
$4.32
52 Week High
$33.19
$17.66

Technical Indicators

Market Signals
Indicator
KE
PRTA
Relative Strength Index (RSI) 56.74 59.50
Support Level $28.24 $10.14
Resistance Level $29.93 $11.57
Average True Range (ATR) 0.95 0.57
MACD 0.23 0.06
Stochastic Oscillator 87.43 71.70

Price Performance

Historical Comparison
KE
PRTA

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: